MARKETS
Analyst Actions

HC Wainwright & Co. Reiterates Buy on Definium Therapeutics, Maintains $70 Price Target

Sep 14, 2026 · 10:55 AM ET· updated 2d ago

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Definium Therapeutics (NASDAQ:DFTX) with a Buy and maintains $70 price target.

Share
Why It Matters

An analyst still thinks Definium stock is a good buy and stays confident. They think the stock could be worth around $70 per share.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.